A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has created a number of websites to better serve you with specific questions.
To support Amgen’s mission of serving patients, the R&D organization aims to discover, develop, and deliver transformative medicines that address the leading causes of death and disability, working to meet the needs of as many patients as possible. To achieve this vision, we need to take full advantage of opportunities arising from rapid scientific progress and new technologies. Biotechnology and the data sciences are advancing at blinding speed, opening up immense new possibilities. At the same time, competition within the industry is intensifying, and access hurdles to medicines are more numerous and steeper.
To keep pace with these rapidly changing opportunities and challenges, Amgen has adopted a dynamic R&D strategy. It is designed to:
Amgen’s scientific success has been rooted in a unique “triple threat” capability that includes world-class human genetics, a deep understanding of disease biology, and the molecular engineering expertise needed to design the right drug for the right target. By building on Amgen’s long-standing strengths in science and biotechnology, we’re confident we can deliver solutions that patients need and society will embrace.
— David M. Reese, Executive Vice President, Research and Development
Benefit patients and societies through transformative medicines.
Improve our success rates. Focus our people and investments more intensely on the activities most likely to lead to new therapies.
Reduce cycle times. The industry’s standard timeline of 12 to 14 years from project start to drug approval is not viable. Amgen has already reduced its drug development timelines by about three years, but there is still ample room for improvements.
Enable access and use. Gaining regulatory approval for new therapies is only half the battle. In the end, only one metric matters: Are the patients who need Amgen medicines actually getting them?
Make focused investment in innovative research platforms
Innovate in Clinical Development
Address access and use at all stages of drug development